Apigenin Regulates Matrix Metalloproteinase-2/9 and RHO GTPase family through FAK signal to reduce Breast Cancer MCF-7 cells Metastasis

Yuan-Wei Shih*, Shang-Tao Chien, Ming-Der Shi
Department of Food Nutrition, Chung Hwa University of Medical Technology, No. 89, Wen-Hwa 1st Street, Jen-Te, Tainan 71703, Taiwan

Corresponding Author: Yuan-Wei Shih, Department of Food Nutrition, Chung Hwa University of Medical Technology, No. 89, Wen-Hwa 1st Street, Jen-Te, Tainan 71703, Taiwan. Tel: 886-6-2671214, E-mail: shih723@seed.net.tw

Citation: Yuan-Wei Shih et al. (2017), Apigenin Regulates Matrix Metalloproteinase-2/9 and RHO GTPase family through FAK signal to reduce Breast Cancer MCF-7 cells Metastasis. Int J Biotech & Bioeng. 3:7, 258-267. DOI: 10.25141/2475-3432-2017-7.0249

Copyright: ©2017 Yuan-Wei Shih et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Received: June 14, 2017; Accepted: July 06, 2017; Published: September 15, 2017

Abstract

Cancer metastasis is the toughest problem in cancer therapy. Once tumor cells have the ability of surrounding cell invasion, the survival rate of patient with tumor disease will be reduced. Hence, prevent or reduce the cancer metastasis will can increase the patients’ survival rate. Apigenin has been demonstrated optimal effect in cancer prevention and reduce cancer metastasis, including breast cancer. In this study, we verify low dose (≦5 μg/ml) apigenin exposure 3 h would not influence the MCF-7 cells viability but can decrease its FAK signal activation to reduce matrix metalloproteinases (MMP-2 and MMP-9) expression. Moreover, low dose apigenin treated in MCF-7 cells could reduce the cell mobility through the Rho GTPases (Ras, Rac-1, cdc-42, and RhoA) downregulation to cause cytoskeleton remodeling. Presented results have demonstrated the role of apigenin on breast cancer metastasis is associated with FAK signal pathway inhibition. The capacity of low dose apigenin treated in breast cancer for short time has been clarified here. And thus may find widespread application in clinical therapy as an anti-metastatic medicament.

Keywords: Cancer metastasis, Apigenin, Matrix metalloproteinases, Rho GTPases

Introduction

Breast cancer is the common cancer of women and the ranking 5th leading cause of death worldwide [1]. The risk factor of breast cancer development including, obesity, drinking alcohol, early age at first menstruation, having children late or not at all, older age, etc. About 5–10% of cases are genomic alteration, including BRCA1 and BRCA2 mutation [2]. Surgery is the major method to remove the tumor. Chemotherapy, radiation therapy and hormone therapy are often used to reduce the recurrence. The majority of early-stage breast cancer patients was undergo breast conserving surgery and then receive adjuvant treatment. The 5-years survival of early-stage breast cancer is 98.6%. While in late-stage, often associated with metastasis, these therapies could not achieve the optimal treatment and cause the survival rate declines to 24.3% [3]. Furthermore, once breast cancer with metastasis will cause poor outcome. Therefore, inhibition of breast cancer metastasis can extend the patients’ survival.

Cancer metastasis is a complex process, the local tumor cells migrate to distant site by the bloodstream, the lymphatic system, or by direct extension. Among them, the epithelial-mesenchymal transition (EMT) is the important characteristics. EMT is the conserved developmental process in the evolution [4], and it also plays pivotal role in cancer metastasis. Cytokines and growth factors, such as transforming growth factor β (TGF-β) are related with EMT dysregulation during the process of malignant tumor [5]. In the EMT process, the cell-cell junction would be breakdown by E-cadherin reducing, and the Rho GTPase function also be modulated, loss of cell polarity ensues, a dramatic reorganization of the actin cytoskeleton to enhance cell motile characteristics [5-7]. Once cancer metastasis, the survival rate of cancer patients would be reduced. But, the molecular mechanism of cancer metastasis happen is unclear. Therefore, in clinical, inhibition of cancer metastasis is the crucial issues to prolong the life of tumor diseases patients.

Apigenin (4’,5,7-trihydroxyflavone) is a plants source natural product, belonging to the flavone class. The functions of apigenin are recognized as anti-inflammatory, antioxidant and anticancer. Apigenin has been shown effective in inhibiting several cancers, including breast cancer [8], lung cancer [9], oral cancer [10], gastric cancer [11], colon cancer [12], bladder cancer [13],...
prostate cancer [14]. It also can induce autophagy in leukemia cell, and simultaneously induces resistance against the vincristine [15]. Moreover, apigenin treatment can enhance cell apoptosis through down regulate bcl-2 expression [16]. Epidemiologic studies indicate that flavones can decrease cancers development, particularly breast cancer [17]. In breast cancer, apigenin has been demonstrated can induce cell apoptosis by inhibiting STAT3 and NFκB signaling [18] and inhibit metastasis through blocking PI3K/Akt pathway and p42 integrin function [19]. These literatures imply apigenin may be involved in EMT change to inhibit breast cancer metastasis. Thus, we try to clarify the inhibition mechanism of breast cancer metastasis through apigenin treatment in this study.

Materials and methods

Reagents and antibodies

Apigenin (Purity > 99%), was purchased from Extrasynthese (Genay, France); DMSO, Tris- HCl, EDTA, SDS, bovine serum albumin (BSA), gelatin, crystal violet, and sodium orthovanadate were purchased from Sigma-Aldrich (St. Louis, MO, USA); the protein assay kit was obtained from Bio-Rad Laboratories (Hercules, CA, USA). Dulbecco’s phosphate buffer solution (PBS), trypsin-EDTA, Dulbecco’s modified Eagle’s medium (DMEM) purchased from Life Technologies, Inc. (Gibco/BRL, Gaithersburg, MD). Antibody against FAK, MAPK, and PI3K/Akt, proteins and phosphorylated proteins were purchased from Cell Signaling Tech. (Beverly, MA, USA). PI3K, MMP-2, MMP-9, Ras, Rac-1, Cdc42, RhoA, RhoB, NF-xB, c-Fos, c-Jun, β-actin, and C23 antibodies were purchased from BD Transduction Laboratories (San Jose, CA, USA). The enhanced chemiluminescence (ECL) kit was purchased from Amersham GE Healthcare UK Ltd. (Buckinghamshire, England).

Cell culture and apigenin treatment

Human breast cancer cells, including MCF-7, MDA-MB-231, and H184BS5F5/M10 were maintained in DMEM medium containing with 10% fetal calf serum and antibiotics (100 U/ml of penicillin and 100 mg/ml of streptomycin). All cells were cultured at 37°C in a humidified atmosphere of 5% CO2-95% air. The stock solution (10 mg/ml in DMSo) of apigenin was dissolved in dimethylsulfoxide (DMSo) and diluted to 200 μg/ml with cold filtered distilled water, and then stored at −20°C. The medium was sterilized by filtration through 0.2 μm disc filters. Suitable amounts of stock solution (10 mg/ml in DMSO) of apigenin were added into the cultured medium to achieve the desired concentrations.

Assessment of cell viability (MTT assay)

To explore the effect of apigenin on breast cancer cell viability, the various concentration (0, 1, 2.5, 5, 7.5, 15, 30, and 45 μg/ml) were respectively treated in MCF-7, MDA-MB-231, and H184BS5F5/M10 cell lines for 24 and 48 h. At the end of the assay period, cell viability was measured by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] assay. Each concentration was repeated three times. After the exposure period, the medium was removed and followed by washing of the cells with PBS. Then, the medium was changed and incubated with MTT solution (5 mg/ml) per well for 4 h. The medium was removed, and formazan was solubilized in isopropanol and measured spectrophotometrically at 563 nm. The percentage of viable cells was estimated by comparing with the untreated control cells (0 μg/ml).

Boyden chamber invasion and migration assay

Matrigel (BD Transduction Laboratories, San Jose, CA) was be diluted to 200 μg/ml with cold filtered distilled water, and then added to the upper chamber with 8μm pore polycarbonate filter. And then the treated MCF-7 cells (1×105 cells/well) were mixture with serum free medium to add into the upper chamber. Culture medium containing with 10% fetal bovine serum was applied to the lower chamber as chemoattractant. The chamber was incubated for 8h at 37°C. At the end of incubation, the cells in the upper surface of the membrane were carefully removed with a cotton swab. The invasive cells were fixed by 3% methanol and then stained by 5% Giemsa solution. The invading cells on the lower surface of the membrane filter were counted with a light microscope. The data are presented as the average number of cells attached to the bottom surface from five random fields. Each experiment was carried out in triplicate.

To measure the migrative ability of MCF-7 cells, cells were seeded on the upper surface of the filter inserts with 8-μm pore polycarbonate filters that were not coated with matrigel. The migrative cells were treated and measured as described in the invasion assay.

Wound-healing assay

To determine cell motility determination, MCF-7 cells (1×105cells/ml) were seeded in 6-well tissue culture plate and grown to 80-90% confluence. After aspirating the medium, the center of the cell monolayers was scraped with a sterile micropipette tip to create a denuded zone (gap) of constant width. Subsequently, cellular debris was washed with PBS, and the cells were exposed to various concentrations of apigenin (0, 1, 2.5, and 5 μg/ml). The wound closure was monitored and photographed at 0, 6, 12, 24, and 48 h with an Olympus CKX-41 inverted microscope and an Olympus E-410 camera. To quantify the migrated cells, pictures of the initial wounded monolayers were compared with the corresponding pictures of cells at the end incubation. Artificial lines fitting the cutting edges were drawn on pictures of the original wounds and overlaid on the pictures of cultures after incubation. Migrated cells across the white lines were counted in six random fields from each triplicate treatment, and data are presented as mean ± SD.

Immunofluorescence assay

To determine the effect of apigenin on EMT and cytoskeleton change, MCF-7 cells (4×105 cells/well) were plated in six-well plates and grown for 24 h and then incubated in the different concentrations of apigenin (0, 1, 2.5, and 5 μg/ml) for 24 h. After the exposure period, the cells were washed with Ca2+/Mg2+ free PBS after cell medium removed. Cells were fixed with 4% paraformaldehyde in PBS for 15 min and incubated with 0.5% Triton X-100 in PBS for 5 min. Cells were incubated with 1% bovine serum albumin in 0.5% PBST at room temperature for 1 h. And then add the primary antibody or phallolidin-PE (Invitrogen, Karlsruhe, Germany) to incubate at room temperature for 1 h. The fluorescent images were visualized with a BX51 fluorescence microscope (Olympus, Tokyo, Japan).

Analysis of MMP-2/9 activity by gelatin zymography
MCF-7 cells (4×105 cells/ml) were seeded into the 10 cm culture dish and then incubated in the different concentrations of apigenin (0, 1, 2.5, and 5 μg/ml) for 24 h. Subsequently, the conditioned medium was collected and gelatin zymography was performed to examine the activities of MMP-2 and MMP-9. Samples were mixed with loading buffer and electrophoresed on 8% SDS-polyacrylamide gel containing 0.1% gelatin. Electrophoresis was performed at 140 and 110 V for 3 h. Gels were then washed twice in zymography washing buffer (2.5% Triton X-100 in double-distilled H2O) at room temperature to remove SDS, followed by incubation at 37°C for 12-16 h in zymography reaction buffer (40 mM Tris-HCl, 10 mM CaCl2, 0.02% NaN3), stained with Coomassie blue R-250 (0.125% Coomassie blue R-250, 0.1% amino black, 50% methanol, 10% acetic acid) for 1 h and destained with destaining solution (20% methanol, 10% acetic acid, 70% double-distilled H2O). Nonstaining bands representing the levels of the latent forms of MMP-2 and MMP-9 were quantified by densitometer measurement using a digital imaging analysis system.

**Reverse transcriptase polymerase chain reaction (RT-PCR)**

Total RNA was isolated from MCF-7 cells using the total RNA Extraction Midiprep System (Viogene BioTek, Taiwan). Total RNA (2 μg) was transcribed to 20 μl cDNA with 1 μl deoxynucleotide triphosphate (dNTP; dNTP set consists of 2.5 mM aqueous solutions at pH 7.0 of each of dATP, dCTP, dGTP, and dTTP), 1 μl Oligo dT (10 pmol/ml), 1 μl RTase (200 U), 1 μl RNase inhibitor and 5× reaction buffer. The appropriate primers (sense of MMP-2, 5'-GGCCCTGTCACTCCTGAGAT-3', nt 1337-1356; antisense of MMP-2, 5'-GGCATCC AGGTATCGGGGA-3', nt 2026-2047; sense of MMP-9, 5'-AGGCTTCTAGAGCTTCC-3', nt 1201-1220; antisense of MMP-9 were used for polymerase chain reaction (PCR) amplifications. PCR was performed with Platinum Taq polymerase (Invitrogen, San Diego, CA, USA) under the following conditions: 30 cycles of 94°C for 1 min, 59°C (MMP-2) or 60°C for 1 min (MMP-9 and β-actin), 72°C for 1 min followed by 10 min at 72°C. The final products were electrophoresis in 2% agarose gel and then detected through ethidium bromide staining.

**Preparation of whole-cell lysates and nuclear extracts**

Lysis cell in iced-cold RIPA buffer (1 % NP-40, 50 mM Tris-base, 0.1% SDS, 0.5% deoxycholic acid, 150 mM NaCl, pH 7.5) and then add the protease inhibitors (phenyl-methylsulfonyl fluoride (100 mM), leupeptin (100 mM)), and sodium orthovanadate (100 mM). After vortexing for 30 min on ice, the samples were centrifuged at 12000×g for 10 min, and then the supernatants were collected, denatured and subjected to SDS-PAGE and Western blotting. Nuclear extracts were prepared as previously described. Each nuclear pellet was resuspended in nuclear extract buffer (1.5 mM MgCl2, 10 mM HEPES, pH 7.9, 0.1 mM EDTA, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 25% glycerol, and 420 mM NaCl). The nuclear suspension was incubated on ice for 20 min and then centrifuged at 14,000×g for 5 min. The supernatant (corresponding to the soluble nuclear fraction) was saved, and then used for NF-kB (p65 and p50), c-Jun and c-Fos detection. The protein content was determined with Bio-Rad protein assay reagent using bovine serum albumin as a standard.

**Western blotting analysis**

The denatured samples (50 μg extracted protein) were resolved on 10-12% SDS-PAGE gels. The proteins were then transferred onto nitrocellulose membranes. Non-specific binding of the membranes was blocked with Tris-buffered saline (TBS) containing 1% (v/v) nonfat dry milk and 0.1% (v/v) Tween-20 (TBST) for more than 2 h. Membranes were washed with TBST three times for 10 min and incubated with an appropriate dilution of specific primary antibodies in TBST overnight at 4°C. Subsequently, membranes were washed with TBST and incubated with appropriate secondary antibodies (horseradish peroxidase-conjugated goat antimouse or antirabbit IgG) for 1 h. After washing the membranes three times for 10 min in TBST, the bands detection were revealed by enhanced chemiluminescence using ECL Western blotting detection reagents and exposed ECL hyperfilm in FUJIFILM Las-3000 mini (Tokyo, Japan). Then proteins were quantitatively determined by densitometry using FUJIFILM-Multi Gauge V3.0 software.

**Statistical analysis**

Data were expressed as means ± standard deviation of three independent experiments and statistical analysis was obtained using a Student’s t-test. All statistical analyses of data were performed using Sigma Plot 2001 software (Systat Software Inc., San Jose, Calif., U.S.A.). Significant differences were established at P ≤ 0.05.

**Results**

Low dose (<5 μg/ml) apigenin no effect the cell viability, but suppress the MCF-7 cells migration and invasion.

To explore the optimal concentration of apigenin to influence breast cancer cell, the MTT assay is used here. The concentration of apigenin including 0, 1, 2.5, 5, 7.5, 15, 30, and 45 μg/ml were respectively treated in MCF-7, MDA-MB-231 and H184B5F5/M10 breast cancer cell lines. After treatment for 24 or 48 h, we noticed low dose (<5 μg/ml) apigenin no toxicity in MCF-7 cells, and the cell viability can achieve 80%. However, once the dose of apigenin more than 5 μg/ml, the cell viability dramatic decrease. But, this phenomenon could not observe in MDA-MB-231 cells.
In pathologic characteristics, the MDA-MB-231 cell is basal type breast cancer cell and associated with poor prognosis, in turn, MCF-7 cell is a luminal type breast cancer have better 5-years survival rate. Imply the low dose apigenin treatment in luminal type breast cancer can achieve the optimal treat efficiency more than in basal type.

Next, we explore the role of apigenin in MCF-7 cells under the low dose treatment. Apigenin has been shown can inhibit invasion and migration in colorectal cancer [20]. In cell migration assay and cell invasion assay, we observe the phenomenon of cell migration was reduced and the invasive cells were significantly decreased. These results suggest that the optimal concentration of apigenin in breast cancer cell treatment is ≤ 5 μg/ml to reduce cell migration and invasion.
Low dose apigenin reduce the MMP-2/9 and EMT expressions

Known the low dose apigenin can reduce the MCF-7 cells migration and invasion during 24 h treatment, we next to verify the MMP-2 and MMP-9 expression under 3 h exposure of low dose apigenin. In the zymography results, we observed the MMP-2 and MMP-9 decreasing in MCF-7 cells after low dose apigenin exposure (Fig. 2a). In the meantime, we noticed the RNA level of MMP-2 and MMP-9 were not change (Fig. 2b), suggest that exposure 3h of low dose apigenin is influence protein expression rather than genomic change. The results imply the apigenin can inhibit breast cancer metastasis through matrix metalloproteinase and plasminogen activator down regulation. We next try to clarify the EMT change whether manifested in MCF-7 cells after exposure 3 h of low dose apigenin. After fluorescence microscopy imaging, we noticed the E-cadherin increase and the fibronectin decrease in MCF-7 cells under the low dose apigenin exposure (Fig. 2c). These results imply the low dose apigenin can inhibit MCF-7 cells metastasis through MMP-2 and MMP-9 down regulation. In addition, it also can down-regulate EMT after apigenin exposure 3 h.

Apigenin inhibit the MCF-7 cells metastasis through FAK signals

To clarify the molecule mechanism of breast cancer metastasis could be inhibited by low dose apigenin exposure 3 h, we use the western blot experiment to demonstrate. Literatures indicate apigenin can regulate PI3K/Akt signal pathway to inhibit breast cancer cell metastasis [19], and promote apoptosis via a caspase-dependent mechanism [21]. The PI3K/Akt signal is the down stream of Focal Adhesion Kinase (FAK). FAK transmits signal to the cell interior through the candidate proteins phosphorylation and dephosphorylation to cause MMP-9 decreased while metastasis reduced [22]. However, we noticed the MMP-2, and MMP-9 were decreased after low dose apigenin exposure for 3 h, imply FAK signal is the major pathway to regulate breast cancer cell metastasis in this study. Thus, we try to analysis the ERK1/2, p38, JNK1/2, and PI3K that are the FAK signals candidates, and noticed the JNK signal was dramatically inhibited in the MCF-7 cells after apigenin treatment (Fig. 3a). The ERK1/2 and Akt were also slightly decreased. In the meantime, the nuclear NFκB, c-Fos, and c-Jun were downregulated (Fig. 3b), illustrate the FAK signal can be inhibited by apigenin exposure 3 h.
Apigenin can regulate the cytoskeleton change to inhibit the MCF-7 cells metastasis

As described above, low dose apigenin exposure 3 h down-regulate MMP-2 and MMP-9 through FAK inhibition. On the other hand, we also noticed cytoskeleton regulator influence in the low dose apigenin exposure 3 h. The Ras, Rac-1, Cdc42, and RhoA were the downstream of FAK associated with cytoskeleton remodeling. Known the Ras and Rac-1 are related with lamellipodia, the Cdc42 is a regulator in filopodia, and the RhoA is associated with stress fiber formation. Here, we observed the Ras and Rac-1 obviously down regulation after low dose apigenin exposure 3 h as compared with Cdc-42 and RhoA (Fig. 4a). After fluorescence microscopy imaging, we also observed the lamellipodia was not obviously express in MCF-7 cells after low dose apigenin exposure 3 h (Fig. 4b). The results suggest that apigenin inhibit breast cancer cell metastasis is through FAK signal down regulation to cause matrix metalloproteinase decreasing and cytoskeleton remodeling (Fig. 5).
Discussion

Tumor metastasis is the toughest problem in cancer therapy. Once tumor cell metastasis, anticancer drugs could not achieve the optimal efficiency, and the survival rate of patients with cancer also would reduced. Thus, avoid or reduce the phenomena of cancer metastasis is the most important issue in the cancer research. Cancer metastasis is the process of EMT. The epithelial cells lose their cell polarity and cell-cell adhesion, and enhance its migratory and invasive properties to become mesenchymal cell type. EMT is also critical for development of many tissues and organs in the developing embryo and numerous embryonic events [23]. Many markers have been considered to be a fundamental event in EMT, such as loss expression of E-cadherin, type IV collagen or laminin In the meantime, increase the expression of N-cadherin, vimentin, or fibronectin…etc [24]. EMT is also involved in cytoskeleton remodeling [25] and the extracellular matrix (ECM) damaged [26]. Matrix metalloproteinases (MMPs) play key functions in degrade and modify the ECM, gelatin-cleaving MMPs (MMP-2 and -9) were the frequently molecule explored in cancer research with metastasis. In this study, we verify the MMP-2 and -9 were down regulation after low dose apigenin exposure 3h.

On the other hand, EMT is also a process of cytoskeleton change. The actin cytoskeleton is a highly dynamic structure manifested in all live cells. It is based on well-balanced of the local assembly and disassembly of actin filaments. Rho GTPases are the mainly responsible of transmitting signals from chemokine and growth factor receptors and from adhesion receptors to the effector of actin remodeling candidates, including RhoA, Rac1 and Cdc42. The activity of RhoA during EMT is effects cell-cell adhesion, Ras and Rac1 enhance the formation of protrusive membrane structures, such as lamellipodia and Cdc42 can influence filopodia that are rod-like extension consisting of tight bundled actin fibers which penetrate into the surrounding environment originating from the basis of lamellipodia. In this study, we noticed the Ras and Rac-1 is decreased after low dose apigenin treatment implies the low dose apigenin can decrease lamellipodia formation to reduce cell motility.

Apigenin has been demonstrated strong inhibited hER2/neu over-expressing breast cancer cells growth, but it was much less effective in inhibiting growth of cells expressing basal levels of HER2/neu [27]. Many studies were verifying the effect of apigenin on breast cancer cell (tab. 1). In these studies, 24-48 h exposure time of apigenin treated in MCF-7 or MDA-MB-231 cells were the most used to against the cell growth. the MApk and pI3k/Akt pathways were the most clarify in these studies. however, FAK signal is the less described in breast cancer cell after apigenin exposure. here, we observed the cell growth could not be inhibited in basal type breast cancer cell line, MDA-MB-231 in the 1-45 μg/ml of apigenin exposure 24 or 48 h. Suggest that apigenin treated in basal type breast cancer cell needs to take longer exposure time.
That is to say, low dose apigenin exposure 3 h in breast cancer can achieve optimal effect is in the luminal type rather than basal type. Nevertheless, low dose apigenin treatment is sufficient to effect breast cancer cell cytoskeleton remodeling and decreasing the matrix metalloproteinases expression through FAK signal to reduce metastasis were verified in this study. In terms of cancer therapy, low dose apigenin exposure short time may be the potential for reduces lumina type cancer cell metastasis.

| Year | Author | Cell line | Apigenin conc. | Incubation time | Target molecule | Inhibition |
|------|--------|-----------|----------------|----------------|----------------|------------|
| 2001 | Yin F, et al | MCF-7 and MDA-MB-468 | 7.8 or 8.9 µg/ml | 72 h | cyclin-CDK regulators, ERK MAP kinase | Cell cycle |
| 2001 | Lindenmeyer F, et al | MDA-MB-231 | 2.5 µg/ml (22.8µM) | 24 and 48h | MAPK | Protease expression, cell migration, cell adhesion to the ECM, and cell proliferation |
| 2004 | Wei TD, et al | MDA-MB-453, BT-474, and SKBr-3 | 40 µM | 24 and 48h | PI3K/Akt | Cell growth (Induce apoptosis by depleting HER2/new protein) |
| 2006 | Seo HS, et al | MCF-7 and T47D cells (ERa positive) MDA-MB-435 (ERa negative) | 0.1% of culture medium | 24 and 48h | ERβ | Cell proliferation |
| 2006 | Mak P, et al | MDA-MB-231 | 20 µM | 24h | ERβ | Cell proliferation |
| 2006 | Fang J, et al | MCF-7 | 20 µM | 1h | HIF-1α and VEGF | Angiogenesis |
| 2007 | Chen D, et al | MDA-MB-231 | 25–100 µM | 24h | Chymotrypsin-like protease | Chymotrypsin-like protease activity |
| 2008 | Long X, et al | MCF-7 | 10 µM | 24h | p38, PKA, MAPK and AKT | Antiestrogen-resistant breast cancer cell growth |
| 2008 | Lee WJ, et al | MDA-MB-231 | 40 µM | 12 and 24h | PI3K/Akt and integrin β4 function | HGF-induced invasive growth |
| 2009 | Choi EJ, et al | SK-BR-3 | 1–100 µM | 24 and 48h | CDK1, p21Waf1 and p53 | Cell cycle |
| 2010 | Mafuvadze B, et al | T47-D and BT-474 | 50 or 100 µM | | VEGF | Angiogenesis |
| 2013 | Cao X, et al | T47-D and MDA-MB-231 | 6 µM | 24 and 48h | PI3K/Akt/mTOR | Cell proliferation (through inducing apoptosis and autophagy) |
| 2014 | Harrison ME, et al | MDA-MB-231, MBA-MB-468, MCF-7, SK-BR-3 | 10–30 µM | 24 and 72h | PI3K/Akt | Cell growth, oxidative stress, and hypophosphorylation of Akt |
| 2014 | Bai H, et al | MCF-7 | 80 µM | 72h | STAT3 | Cell growth |
| 2014 | Seo HS, et al | MDA-MB-231 | 0–60 µM | 72h | STAT3 | Cell proliferation |

Tab. 1 The study of breast cancer and apigenin effect were described in below.
Acknowledgement
This study was supported by a grant from the Research Program of Kaohsiung Armed Forces General Hospital (Project Number: 101-29).

Abbreviations
MMPs  Matrix metalloproteinases
ERK  Extracellular signal-regulated kinase
PI3K  Phosphoinositide 3-kinase
FAK  Focal adhesion kinase
SDS-PAGE  SDS-polyacrylamide gel electrophoresis
ECL  Enhanced-chemiluminescent
NF-κB  Nuclear factor kappa B

Reference
1. McGuire, S. (2016). World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Advances in Nutrition 7, 418–419
2. Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., et al. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European Journal of Cancer 46, 2275–2284.
3. Miller, K. D., Siejel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Ronland, J. H., et al. (2016). Cancer treatment and Survivorship Statistics, 2016. CA: A Cancer Journal for Clinicians 66, 271–289.
4. Thiery, J. P. (2003). Epithelial-mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology 15, 740–746.
5. Singh, A., Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751.
6. Yang, J., Weinberg, R. A. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental Cell 14, 818–829.
7. Yilmaz, M., Christofori, G. (2009). EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Reviews 28, 15–33.
8. Long, X., Fan, M., Bigsby, R. M., Nephew, K. P. (2008). Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-α-dependent and -independent Mechanisms. Molecular Cancer Therapeutics 7, 2096–2108.
9. Lu, H. F., Chie, Y. J., Yang, M. S., Lee, C. S., Fu, J. J., Yang, J. S., et al. (2010). Apigenin induces caspase-dependent apoptosis in human lung cancer A549 cells through Bax- and Bel-2-triggered mitochondrial pathway. International Journal of Oncology 36, 1477–1484.
10. Maggioni, D., Garavello, W., Rigolio, R., Pignataro, L., Gaini, R., Nicolini, G. (2013). Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis. International Journal of Oncology 43, 1675–1682.
11. Kuo, C. H., Weng, B. C., Wu, C. C., Yang, S. F., Wu, D. C., Wang, Y. C. (2014). Apigenin has anti-atrophic gastritis and anti-gastric cancer progression effects in Helicobacter pylori-infected Mongolian gerbils. Journal of Ethnopharmacology 151, 1031–1039.
12. Wang, Q. R., Yao, X. Q., Wen, G., Fan, Q., Li, Y. J., Fu, X. Q., et al. (2011). Apigenin suppresses the growth of colorectal cancer xenografts via phosphorylation and up-regulated FADD expression. Oncology Letters 2, 43–47.
13. Zhu, Y., Mao, Y., Chen, H., Lin, Y., Hu, Z., Wu, J., et al. (2013). Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell International 13, 54.
14. Zhu, Y., Wu, J., Li, S., Wang, X., Liang, Z., Xu, X., et al. (2015). Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer. Molecular Medecine Reports 11, 1004–1008.
15. Ruela-de-Sousa, R. R., Fuhler, G. M., Blom, N., Ferreira, C. V., Aoyama, H., Peppelenbosch, M. P. (2010). Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death and Disease 1, 1–11.
16. Papachristou, F., Chatzaki, E., Petrou, A., Kougioumtzi, I., Katsikogiannis, N., Papalambros, A., et al. (2013). Time course changes of anti- and pro-apoptotic proteins in apigenin-induced genotoxicity. Chinese Medicine 8, 9.
17. Skukla, S., Gupta, S. (2010). Apigenin: A Promising Molecule for Cancer Prevention. Pharmaceutical Research 27, 962–978.
18. Seo, H. S., Choi, H. S., Kim, S. R., Choi, Y. K., Woo, S. M., Shin, I., Woo, et al. (2012). Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells. Molecular and Cellular Biochemistry 366, 319–334.
19. Lee, W. J., Chen, W. K., Wang, C. J., Lin, W. L., Tseng, T. H. (2008). Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and β4 integrin function in MDA-MB-231 breast cancer cells. Toxicology and Applied Pharmacology 226, 178–191.
20. Li C, Lin D, fu X, Zhang L, fan Q, Liu Y , et al. (2013). Apigenin up-regulates transgelen and inhibits invasion and migration of colorectal cancer through decreased phosphorylation of AKT. The Journal of Nutritional Biochemistry 24, 1766–1775.
21. Seo, H. S., Ku, J. M., Choi, H. S., Woo, J. K., Jang, B. H., Shin, Y. C., et al. (2014). Induction of Caspase-dependent Apoptosis by Apigenin by Inhibiting STAT3 Signaling in HER2-overexpressing MDA-MB-453 Breast Cancer Cells. Anticancer Research 34, 2869–2882.
22. Ganguly, K. K., Sen, T., Pal, S., Biswas, J., Chatterjee, A. (2012). Studies on Focal Adhesion Kinase in human breast cancer cell MDA-MB-231. Advances in Biological Chemistry 2, 29–42.
23. Thiery, J. P., Acloque, H., Huang, R. Y., Nieto, M. A. (2009). Epithelial-Mesenchymal Transitions in Development and Disease Cell 139, 871–890.
24. Shih, J. Y., Yang, P. C. (2011). The EMT regulator slug and lung carcinogenesis. Carcinogenesis 32, 1299–1304.
25. Haynes, J., Srivastava, J., Madson, N., Wittmann, T., Barber, D. L. (2011). Dynamic actin remodeling during epithelial–mesenchymal transition depends on increased moesin expression. Molecular Biology of The Cell 22, 4750–4764.
26. Kumar, S., Das, A., Sen, S. (2014). Extracellular matrix density promotes EMT by weakening cell-cell adhesions. Molecular Biosystems 10, 838–850.
27. Way, T. D., Kao, M. C., Lin, J. K. (2004). Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. Journal of Biological Chemistry 279, 4479–4489.